Table 3.
Number, proportion (%) of participants and prevalence ratio of symptoms, by antibody status, DSS-II and DSS-III, Denmark 2020
| Symptoma | Antibody test result | |||||
|---|---|---|---|---|---|---|
| Positive (n = 369) | Negative (n = 12 726) | Prevalence ratio | 95%CI | |||
| Number | Proportion (%) | Number | Proportion (%) | |||
| No symptoms reported | 112 | (30) | 7232 | (57) | 0.53 | (0.46–0.62) |
| At least one core symptomb | 216 | (59) | 3508 | (28) | 2.1 | (1.9–2.3) |
| Fever | 139 | (38) | 1801 | (14) | 2.7 | (2.3–3.1) |
| Cough | 141 | (38) | 2544 | (20) | 1.9 | (1.7–2.2) |
| Shortness of breath | 71 | (20) | 811 | (6) | 2.8 | (2.2–3.5) |
| Loss of sense of smell or taste | 104 | (28) | 367 | (3) | 9.8 | (8.1–12) |
| Other symptomsc | 41 | (11) | 1986 | (16) | 0.71 | (0.53–0.95) |
aIn the period since 1 February 2020
bCore symptoms includes one or more of the following: fever, cough, shortness of breath and/or loss of sense of taste or smell
cMuscle ache, eye pain, head ache, coloured sputum, runny nose, sneezing, back pain, tiredness without one of the core symptoms
DSS: Danish National Seroprevalence Survey of SARS-CoV-2 infection